CSRxP: SENATE JUDICIARY COMMITTEE SHOULD REJECT PHARMA-SUPPORTED POLICIES THAT WOULD UNDERMINE BIPARTISAN PROGRESS ON PATENT ABUSE
Lawmakers Should Remain Focused on Holding Big Pharma Accountable for… Read More
Lawmakers Should Remain Focused on Holding Big Pharma Accountable for… Read More
Legislation Scheduled for Thursday Markup Would Encourage Adoption of… Read More
HELP Committee Hearing an Opportunity to Highlight Staggering Cost… Read More
Lowering Prices for Some Patients at Some Dosages Will Have Limited Impact,… Read More
Bipartisan, Market-Based Solution Would Help Crack Down on Anti-Competitive… Read More
Brand Name Drug Giants’ Average Price Increases for June-July Outpace Rate… Read More
Legislation Would Hold Big Pharma Accountable for Anti-Competitive Tactics… Read More
Latest Data Finds List Prices of Prescription Drug Prices Have Increased… Read More
President Says ‘Drug Companies Are Charging Exorbitant Prices’ in Press… Read More
Commission Targets More Than 100 Patents on Brand Name Products Listed in the… Read More
Senate Panel Passes Bills to Increase Competition and Increase List Price… Read More
Bipartisan Interagency Patent Coordination and Improvement Act of 2022 Will… Read More